Loading...
XLONIXI
Market cap13mUSD
Dec 23, Last price  
11.50GBP
1D
-2.13%
1Q
21.05%
Jan 2017
-63.49%
IPO
-77.67%
Name

IXICO PLC

Chart & Performance

D1W1MN
XLON:IXI chart
P/E
P/S
159.89
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
7.43%
Rev. gr., 5y
4.32%
Revenues
7m
-22.89%
1,072,0007,378,0001,883,0003,121,0002,623,000867,000697,00067,00018,71710,0002,559,7503,115,0003,268,0004,099,9995,394,0007,561,0009,532,0009,190,0008,643,0006,665,000
Net income
-1m
L
-6,225,940-3,326,200-5,639,000-5,813,000-2,275,000-3,911,000-3,802,000-7,658,000-7,766,309-4,767,000-1,719,000-1,194,000-2,119,000-1,537,000-668,000432,000952,0001,512,0001,032,000-1,178,000
CFO
302k
-78.88%
-5,831,000-3,794,000-5,849,000-5,456,000-2,582,000-3,400,000-4,442,000-6,424,000-8,995,375-4,438,000-1,705,500-1,316,000-1,535,000-644,000355,000-130,0001,937,000614,0001,430,000302,000
Earnings
May 19, 2025

Profile

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.
IPO date
Sep 04, 2013
Employees
90
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
6,665
-22.89%
8,643
-5.95%
Cost of revenue
8,495
8,897
Unusual Expense (Income)
NOPBT
(1,830)
(254)
NOPBT Margin
Operating Taxes
(183)
(463)
Tax Rate
NOPAT
(1,647)
209
Net income
(1,178)
-214.15%
1,032
-31.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
2
BB yield
-0.02%
Debt
Debt current
112
122
Long-term debt
662
788
Deferred revenue
Other long-term liabilities
2
33
Net debt
(3,257)
(4,859)
Cash flow
Cash from operating activities
302
1,430
CAPEX
(100)
(2,245)
Cash from investing activities
(1,864)
(2,245)
Cash from financing activities
(156)
(114)
FCF
612
256
Balance
Cash
4,031
5,769
Long term investments
Excess cash
3,698
5,337
Stockholders' equity
458
(72,309)
Invested Capital
11,363
85,295
ROIC
0.24%
ROCE
EV
Common stock shares outstanding
48,309
50,758
Price
0.19
-43.28%
0.34
-58.13%
Market cap
9,179
-46.02%
17,004
-57.84%
EV
5,922
12,145
EBITDA
(1,205)
385
EV/EBITDA
31.55
Interest
29
33
Interest/NOPBT